Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$1.39 +0.7%	$1.44	$0.73 ▼ $3.28	$87.82M	0.62	315,816 shs	209,138 shs
INZY Inozyme Pharma	$1.18 +2.6%	$1.03	$0.72 ▼ $6.24	$76.18M	1.35	514,895 shs	619,332 shs
NBTX Nanobiotix	$3.33 -2.3%	$3.37	$2.76 ▼ $7.51	$156.95M	0.26	15,083 shs	1,993 shs
TCRT Alaunos Therapeutics	$2.85	$2.26	$1.31 ▼ $13.30	$4.67M	-1.08	136,099 shs	7,287 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	+0.72%	+6.11%	+2.96%	+6.11%	-54.13%
INZY Inozyme Pharma	+1.72%	-20.81%	+33.17%	-8.53%	-74.01%
NBTX Nanobiotix	-2.35%	-6.83%	0.00%	-19.17%	-49.55%
TCRT Alaunos Therapeutics	0.00%	0.00%	-2.40%	+72.21%	-77.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GALT Galectin Therapeutics	1.0586 of 5 stars	3.0	0.0	2.6	1.7	0.0
INZY Inozyme Pharma	3.2268 of 5 stars	4.5	1.0	3.3	2.5	0.6
NBTX Nanobiotix	1.6704 of 5 stars	3.3	3.0	1.8	0.0	0.6
TCRT Alaunos Therapeutics	0.4243 of 5 stars	0.0	2.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	2.00	Hold	$11.00	691.37% Upside
INZY Inozyme Pharma	3.00	Buy	$14.63	1,139.41% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	140.24% Upside
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GALT, TCRT, INZY, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/12/2025	INZY Inozyme Pharma	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $12.00
3/11/2025	INZY Inozyme Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $23.00
3/11/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/11/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
3/10/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $7.00
2/17/2025	NBTX Nanobiotix	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.01) per share	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
NBTX Nanobiotix	-$11.61M	-13.52	N/A	N/A	($0.04) per share	-83.25
TCRT Alaunos Therapeutics	$10K	467.40	N/A	N/A	$3.93 per share	0.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$41.07M	-$0.76	N/A	N/A	N/A	N/A	N/A	-163.15%	5/21/2025 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.63	N/A	N/A	N/A	N/A	-88.42%	-57.02%	5/13/2025 (Estimated)
NBTX Nanobiotix	-$42.97M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	5/20/2025 (Estimated)
TCRT Alaunos Therapeutics	-$35.14M	N/A	0.00	∞	N/A	N/A	-267.77%	-209.18%	5/13/2025 (Estimated)

Latest GALT, TCRT, INZY, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	1.13	1.13
INZY Inozyme Pharma	0.51	7.68	7.68
NBTX Nanobiotix	N/A	1.42	N/A
TCRT Alaunos Therapeutics	N/A	4.30	4.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
INZY Inozyme Pharma	88.30%
NBTX Nanobiotix	38.81%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	50.10%
INZY Inozyme Pharma	11.19%
NBTX Nanobiotix	3.45%
TCRT Alaunos Therapeutics	5.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	63.18 million	31.32 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.52 million	No Data

GALT, TCRT, INZY, and NBTX Headlines

Recent News About These Companies

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.com

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 16, 2024 | investorplace.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 12, 2024 | seekingalpha.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 8, 2024 | investorplace.com

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

April 1, 2024 | msn.com

Sharp increase in TCRT’s short interest leads to surge in days-to-cover ratio

February 1, 2024 | knoxdaily.com

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

January 31, 2024 | msn.com

Werewolf Therapeutics Inc (HOWL)

January 31, 2024 | investing.com

Alaunos Therapeutics Inc [TCRT] Insider Boyle Kevin S. Sr. sells 68,014 Shares – Latest Insider Activity

January 3, 2024 | knoxdaily.com

Alaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and Dates

December 28, 2023 | benzinga.com

TCRT Shares Experience Decline in Value

November 17, 2023 | knoxdaily.com

Recap: Alaunos Therapeutics Q3 Earnings

November 14, 2023 | benzinga.com

Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?

November 14, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, TCRT, INZY, and NBTX Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$1.39 +0.01 (+0.72%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$1.37 -0.02 (-1.37%)

As of 04:13 AM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Inozyme Pharma NASDAQ:INZY

$1.18 +0.03 (+2.61%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$1.24 +0.06 (+5.08%)

As of 05/12/2025 07:53 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Nanobiotix NASDAQ:NBTX

$3.31 -0.10 (-3.05%)

As of 05/12/2025 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Alaunos Therapeutics NASDAQ:TCRT

$2.85 0.00 (0.00%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$2.72 -0.13 (-4.39%)

As of 05/12/2025 07:51 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time